Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GK Bio International is a Malaysia-based biotechnology company specializing in regenerative medicine and advanced cellular immunotherapies. The company primarily focuses on the development and application of Natural Killer (NK) cell technology for cancer treatment and Mesenchymal Stem Cell (MSC) therapies for degenerative conditions. Operating with high-standard laboratory facilities, GK Bio provides personalized cell processing services that utilize proprietary expansion protocols to enhance therapeutic efficacy and safety. Their portfolio extends to exosome-based treatments and comprehensive wellness programs aimed at immune system optimization and anti-aging. The company collaborates with international research institutions to integrate cutting-edge biomedical innovations into the Southeast Asian healthcare market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GK Bio International.